Ratings by Jefferies (Peter Welford)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/14/2026 | GlaxoSmithKline | GSK | Maintain | Buy (N/A) |
|
Details | ||
| 9/4/2025 | Sanofi | SNY | Maintain | Buy (N/A) |
|
Details | ||
| 9/3/2024 | Novartis | NVS | Downgrade | Hold (Buy) |
120.42 (156.24) |
29.75% | Details | |
| 5/14/2024 | Novartis | NVS | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2024 | Sanofi-Aventis | SNY | Maintain | Buy (Buy) |
|
Details | ||
| 1/3/2024 | Novartis | NVS | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2024 | GlaxoSmithKline | GSK | Upgrade | Buy (Hold) |
37.06 (51.96) |
40.21% | Details | |
| 1/3/2024 | AstraZeneca | AZN | Downgrade | Hold (Buy) |
67.35 (92.77) |
37.74% | Details | |
| 9/25/2023 | AstraZeneca | AZN | Upgrade | Buy (Neutral) |
67.02 (92.77) |
38.42% | Details | |
| 7/5/2023 | AstraZeneca | AZN | Maintain | Hold (N/A) |
|
Details | ||
| 5/2/2023 | PureTech Health | PRTC | Maintain | Buy (N/A) |
|
Details | ||
| 5/2/2023 | Novartis | NVS | Maintain | Buy (N/A) |
|
Details | ||
| 4/18/2023 | Sanofi-Aventis | SNY | Maintain | Buy (N/A) |
|
Details | ||
| 4/18/2023 | Novartis | NVS | Maintain | Buy (N/A) |
|
Details | ||
| 4/18/2023 | GlaxoSmithKline | GSK | Maintain | Hold (N/A) |
|
Details | ||
| 4/18/2023 | AstraZeneca | AZN | Maintain | Hold (N/A) |
|
Details | ||
| 1/23/2023 | Galapagos NV | GLPG | Upgrade | Hold (Underperform) |
45.99 (27.73) |
-39.7% | Details | |
| 9/16/2021 | Genmab A/S | GMAB | Downgrade | Hold (Buy) |
42.86 (33.41) |
-22.05% | Details | |
| 7/12/2021 | AstraZeneca | AZN | Maintain | Buy (N/A) |
|
Details | ||
| 5/25/2021 | Vaccitech | VACC | New Coverage | Buy (N/A) |
14.58 (5.00) |
-65.71% | Details | |
| 2/24/2020 | Galapagos NV | GLPG | Maintain | Hold (N/A) |
|
Details | ||
| 11/8/2018 | Compugen | CGEN | Maintain | Buy (N/A) |
|
Details |
